Zocere to Showcase Novel Neuroprotectant Drug at RESI
POSTED: September 30, 2014
BOSTON, September 15, 2014 – - Zocere, Inc., a New Mexico-based pharmaceutical company developing a biologic-based neuroprotectant drug, will be attending the RESI Conference in Boston September 17. The ongoing conference series was created to redefine early stage investments (RESI) by assisting early stage life sciences companies with identifying investors, creating relations, and securing funding for promising drugs, biotechnologies and medical technologies.
Access to capital is one of the biggest barriers to advancing promising technologies, and while Zocere has succeeded in raising a half million dollars from angel investors and a private equity fund, the company is seeking a capital investment of $1 million to $1.5 million in exchange for equity in the company.
The RESI Conference is different from other investor events in that it has created 10 new categories of investors, including family offices, venture philanthropy, patient groups, corporate development, virtual pharma, endowments, foundation, and angels. The unique format attracts entrepreneurs, inventors, and investors from around the world.
Zocere CEO Wayne Laslie and long-time pharmaceutical company executive, believes his company’s drug, which protects the brain post stroke, may connect with Boston area investors. “People can relate to stroke as it touches so many lives. Each year there are an estimated 750,000 acute ischemic strokes in the United States and more than two million worldwide. Yet only three to five percent of stroke victims receive treatment because of risks associated with current therapies. Our drug candidate has the potential to become the first neuroprotectant on the market.”
Zocere’s drug is based upon a STEP protein, a cell-permeable, recombinant peptide, that shows promise as a potent “brain saving” drug when administered after a stroke. It also shows potential for treating other brain trauma, including concussion. The drug was discovered in the laboratory of Dr. Surojit Paul at the University of New Mexico and funded by NIH grants. Zocere has exclusive, global rights to the patent-pending technology. The company needs an influx of funds to further development up to the Investigational New Drug (IND) process.
About Zocere, Inc.
Headquartered in Albuquerque, New Mexico, Zocere is a pharmaceutical company developing injectable neuroprotectant drugs intended to combat stroke and other neurological trauma. Zocere is led by pharmaceutical industry executives with extensive experience in drug commercialization. Visit www.Zocere.com.